Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT07548099
Status
Recruiting
Apply to this trial

Conditions

  • Abdominal Aortic Aneurysm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • 64Cu-DOTA-ECL1i — DRUG
    The radiotracer 64Cu-DOTA-ECL1i will be used to assess the aortic wall in individuals with AAA and age-matched participants without a diagnosis of AAA as a control group.

Study Details

This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography). The aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.

Key Dates

Start date
Apr 30, 2026
Status verified
May 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Participants diagnosed with Abdominal Aortic Aneurysm (AAA)
    Established diagnosis of abdominal aortic aneurysm based on standard clinical criteria.
  • Arm: Control Group
    Age-matched participants without a diagnosis of AAA as a control group.

Primary Outcome Measure

• Measure uptake of 64Cu-DOTA-ECL1 [ Time Frame: 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Penn Medicine; Perelman School of MedicinePhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By research site
Penn Medicine; Perelman School of Medicine· Philadelphia, PA

Related Studies